Crystalline forms of a FGFR inhibitor and processes for preparing the same

US10611762B2 · kind B2 · utility

Assignee

• Incyte Corporation · US

Inventors

• Zhongjiang Jia · Kennett Square, US
• Qun Li · Beijing, CN

Key dates

• Filing date: May 25, 2018
• Grant date: Apr 7, 2020
• Expiry date: May 25, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present disclosure relates to solid forms of N-{[2′-(2,6-difluoro-3,5-dimethoxyphenyl)-3′-oxo-2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-[2,7]naphthyridin]-6′-yl]methyl}acrylamide, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.